Allegiance joins with Cardinal to form $21 billion company
This article was originally published in Clinica
Executive Summary
Allegiance and US pharmaceutical service company Cardinal Health have agreed to merge in a $5.4 billion transaction, including the assumption of around $890 million of debt. The deal will result in a healthcare products and services company with annual revenues of $21 billion and a sales and support staff of over 2,500. The new company will be called Cardinal Health - Allegiance will operate as a wholly-owned subsidiary and will retain its management and name.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.